PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Blüher, M. ; Rosenstock, J.* ; Hoefler, J.* ; Manuel, R.* ; Hennige, A.M.*

Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: A randomised clinical trial.

Diabetologia 67, 758-758 (2024)
Correction DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The graphical abstract (available at https://doi.org/10.1007/s00125-023-06053-9) included a typographical error (‘insulin-dependent insulin secretion’, rather than ‘glucose-dependent insulin secretion’). The online version has been corrected. (Figure presented.).
Altmetric
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Other: Correction, Addition
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Journal Diabetologia
Quellenangaben Volume: 67, Issue: 4, Pages: 758-758 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Berlin ; Heidelberg [u.a.]
Reviewing status Peer reviewed
Institute(s) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF-Topic(s) 30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-506501-001
DOI 10.1007/s00125-024-06095-7
WOS ID 001174347900019
Scopus ID 85184931507
PubMed ID 38349400
Erfassungsdatum 2024-04-22
[➜Report correction]